Loading...
Market
Story
Roche Acquires Poseida for $9.00 per Share, Total Deal Value Up to $1.5 Billion, Representing 215% Premium
Nov 26, 2024, 08:59 AM
Roche Holdings, Inc. has entered into a definitive agreement to acquire Poseida Therapeutics, Inc. for an initial cash payment of $9.00 per share, totaling approximately $1 billion. The deal includes a contingent value right (CVR) that could add up to $4.00 per share, bringing the total potential value of the acquisition to $1.5 billion. This strategic move aims to enhance Roche's portfolio in cell therapies, particularly in the treatment of hematological malignancies and solid tumors. Poseida, known for its development of off-the-shelf CAR-T therapies, has been recognized for its innovative technologies in the biopharmaceutical sector. The acquisition represents a significant premium of around 215% over Poseida's recent closing stock price of $2.86, highlighting Roche's commitment to expanding its capabilities in the cell therapy market.
View original story
Similar markets
Yes • 50%
No • 50%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other Cancer Type • 25%
Cancer Treatment • 25%
Neurology Treatment • 25%
Immunology Treatment • 25%
Other Treatment • 25%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%